세계 소아용 항간질약 시장 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별
Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography
상품코드
:
1424384
리서치사
:
Coherent Market Insights
발행일
:
2024년 01월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
소아용 항간질약 시장 규모는 2023년 12억 240만 달러로 평가되었고 2030년 20억 3,470만 달러에 이를 것으로 예측되며 예측 기간 중 복합 연간 성장률(CAGR) 7.8%를 나타낼 것으로 예측됩니다.
| 보고 범위 |
보고서 세부정보 |
| 기준년 |
2022년 |
2023/2024년 시장 규모 |
12억240만 달러 |
| 과거 데이터 |
2018년-2021년 |
예측 기간 |
2023-2030 |
| 예측기간 2023년/2024년-2030년/2031년 복합 연간 성장률(CAGR): |
7.80% |
2030/2031년 가치 예측 |
20억 3,470만 달러 |
그림 1. 소아용 항간질약 시장 점유율(%), 지역별(2023년)
간질은 세계 모든 연령대의 사람들이 앓고있는 일반적인 신경 질환입니다. 그러나 간질환자의 70% 가까이가 성인이 되기 전에 진단되기 때문에 소아에 보다 많이 보입니다. 항 간질 약물은 간질 발작을 관리하고 간질로 고통받는 소아 환자의 삶의 질을 개선하는 데 중요한 역할을합니다. 이러한 약물은 뇌에서 비정상적인 신경 세포의 발화와 동기화를 제어하여 발작을 예방함으로써 효과를 발휘합니다. 최근, 광범위한 조사개발에 의해 소아용 항간질약으로서 보다 유효하고 부작용이 적은 신세대 항간질약이 개발·승인되었습니다. 이것은 소아 간질 환자의 복용 보험과 치료 성적에 긍정적인 영향을 미칩니다. 소아 간질의 원인은 외상, 출생시 합병증, 유전 질환 등입니다. 수막염과 같은 뇌 감염으로 인해 발병하는 간질을 증후성 간질이라고 하며, 유전과 관련된 질환을 특발성 간질이라고 합니다.
시장 역학
세계 소아용 항간질약 시장은 소아 간질유병률 증가에 의해 견인되고 있습니다. 세계보건기구(WHO)에 따르면 간질은 세계 소아의 약 1%가 병을 앓고 있습니다. 이 외에 의료비 증가, 간질 치료에 대한 의식의 높아짐, 새로운 항간질약의 도입 등의 요인이 시장의 성장을 뒷받침하고 있습니다. 그러나 시장 개척에 드는 비용의 높이나 소아용 의약품의 승인에 관한 규제의 엄격함 등 시장 성장 억제요인도 있습니다. 또한, 항 간질 약물의 소아 신경계에 대한 부작용이 과제가되고 있습니다. 한편, 질병 개질 요법의 연구개발과 개인화된 항간질약 요법의 개발은 향후 시장 참가자들에게 주목할 만한 기회입니다.
본 조사의 주요 특징
- 본 보고서에서는 세계 소아용 항간질약 시장을 상세하게 분석하여 2022년을 기준년으로 한 예측기간(2023년-2030년) 시장 규모 및 연간 평균 성장률(복합 연간 성장률(CAGR)%)을 제공합니다.
- 또한 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장에 대한 매력적인 투자 제안의 행렬에 대해 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계 소아용 항간질약 시장의 주요 기업을 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터에 따라 프로파일하고 있습니다.
- 본 조사의 대상이 되는 주요 기업으로는 사노피, 에자이, 화이자, UCB SA, 사노비온 퍼머슈티컬즈, 애봇, 재즈 퍼머슈티컬즈, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., 다이쇼 제약 홀딩스, Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd. 등이 포함됩니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자 및 각 기업의 경영진은 미래의 제품 시장 - 타이핑, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 소아용 항간질약 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계 소아용 항간질약 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 트렌드 분석
- 시장 역학
- 신경 장애의 발생률 증가
- 연구개발 활동 증가
- 규제 당국에 의한 제품 리콜 증가
- 항간질제의 부작용
- 미개발 신흥 시장
- 표적 요법에 대한 수요 증가
- 영향 분석
- 규제 가이드라인
- 제품 발매
- 주요 개발
- PEST 분석
- Porter's Five Forces 분석
- 규제 시나리오
- 합병과 인수
- 제조업체 수익
- 국가별 건강 관리 지출
제4장 세계 소아용 항간질약 시장-신형 코로나 바이러스 감염증(COVID-19)의 영향 분석
- 전체적인 영향
- 정부의 대처
- COVID-19에 의한 시장에 대한 영향
제5장 세계 소아용 항간질약 시장 - 약제 유형별(2018년-2030년)
- 제1세대 항간질약
- 제2세대 항간질약
- 제3세대 항간질약
제6장 세계 소아용 항간질약 시장 - 투여 경로별(2018년-2030년)
제7장 세계 소아용 항간질약 시장 - 유통 채널별(2018년-2030년)
제8장 세계 소아용 항간질약 시장 - 지역별(2018년-2030년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 기타 라틴아메리카
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 중동
- GCC
- 이스라엘
- 기타 중동
- 아프리카
- 북아프리카
- 중앙 아프리카
- 남아프리카
제9장 경쟁 구도
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB SA
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Marinus Pharmaceuticals, Inc.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
제10장 섹션
BJH
영문 목차
The global anti-epileptic drugs for pediatrics market size is expected to reach US$ 2,034.7 Mn by 2030, from US$ 1,202.4 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.
| Report Coverage |
Report Details |
| Base Year: |
2022 |
Market Size in 2023/2024: |
US$ 1,202.4 Mn |
| Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: |
7.80% |
2030/2031 Value Projection: |
US$ 2,034.7 Mn |
Figure 1. Global Anti-epileptic Drugs for Pediatrics Market Share (%), By Region, 2023
Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.
Market Dynamics
The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.
Key features of the study:
- This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market
Detailed Segmentation:
- Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
- First generation anti-epileptic drugs
- Second generation anti-epileptic drugs
- Third generation anti-epileptic drugs
- Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
- Oral
- Injectable
- Others (Nasal, etc.)
- Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trend Analysis
- Market Dynamics
- Increasing incidence of neurological disorders
- Increasing research and development activities
- Increasing product recalls by regulatory authorities
- Side effects of anti-epileptic drugs
- Untapped emerging markets
- The rising demand for targeted therapy
- Impact Analysis
- Regulatory Guidelines
- Product Launches
- Key Development
- PEST Analysis
- PORTER's Analysis
- Regulatory Scenario
- Mergers and Acquisitions
- Manufacturer Revenue
- Healthcare Spending by Country
4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- First generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Second generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Third generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Others (Nasal, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ovid Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK BIOPHARMACEUTICALS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alexza Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taisho Pharmaceutical Holdings Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Marinus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xenon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
관련자료
